Ipamorelin
Summary
Ipamorelin is a selective growth hormone secretagogue (a ghrelin-receptor agonist) characterized in 1998 preclinical work for releasing GH with minimal cortisol or prolactin elevation. Human data are thin: early pharmacology studies plus one phase 2 trial for postoperative ileus that did not meet its primary endpoint.
Mechanism
Ipamorelin is a five-amino-acid peptide that acts as an agonist at the ghrelin receptor (GHS-R1a) in the pituitary and hypothalamus. Receptor activation triggers a pulse of growth hormone release from somatotrophs. Its distinguishing feature in preclinical work is selectivity: it provokes strong GH release with minimal elevation of cortisol, prolactin, or ACTH, unlike older growth hormone-releasing peptides such as GHRP-6.
Reported effects
Ratings are relative to peers in the same category, not absolute claims.
Studied dosing: research context
Published human work used intravenous administration in early pharmacology studies and a phase 2 trial in bowel-resection patients. No published trial has studied subcutaneous dosing regimens for body-composition or performance outcomes in humans. This describes research protocols, not guidance.
Research context only. This is not a recommendation.
Safety
Human safety data are limited to early pharmacology studies and one phase 2 trial, in which the compound was generally tolerated with no major safety signal reported. There are no long-term safety studies, and no published data on repeated or chronic use in healthy adults. The selectivity profile was established with pharmaceutical-grade material; products of unknown provenance may differ.
Limitations
The only completed human RCT tested ipamorelin for postoperative bowel recovery, not body composition, performance, or aging. It missed its primary endpoint. There are no published trials testing the outcomes the compound is commonly discussed for. Preclinical selectivity findings may not translate to gray-market products of unknown identity and purity.